A novel polyethylene glycol 400 (PEG400) me
diated lipid nanoemulsion as drug-delivery carrier for paclitaxel (PTX) was successfully developed. The formulation comprised a PEG400 solution of the drug (25 mg/mL) that would be mixed with commercially 20% lipid emulsion to form PTX-loaded nanoemulsion (1 mg/mL) prior to use. This two-vial formulation of PTX-loaded lipid nanoemulsion (TPLE) could significantly reduce extraction of reticuloendothelial system (RES) organs and increase tumor uptake, and exhibited more potent antitumor efficacy on bearing A2780 or Bcap-37 tumor nude mice compared to conventional PTX-loaded lipid nanoemulsion (CPLE). TPLE
did not cause haematolysis and intravenous irritation response yet, and showed the same cytotoxicity against HeLa cells as Taxol庐, and its LD
50 was 2.7-fold higher than that of Taxol庐, suggesting its good safety and druggability. In ad
dition, TPLE
displayed
distinctly faster release of PTX, a greater proportion of PTX in phospholipids layer and a smaller share in oil phase than CPLE. From the Clinical E
ditor: This study demonstrates the feasibility and potential advantage of a novel PEG400-me
diated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in clinical application for the cancer therapy.
From the Clinical Editor
This team of investigators convincingly demonstrates the feasibility and potential advantage of a PEG400-mediated two-vial formulation of lipid nanoemulsion as drug carrier for PTX in cancer therapy, documenting superior safety and faster release of PTX compared to commercially available formulations.